Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OptiNose, Inc.
  6. Summary
    OPTN   US68404V1008

OPTINOSE, INC.

(OPTN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
2.6(c) 2.71(c) 2.75(c) 2.84(c) 2.99(c) Last
433 234 391 180 774 181 311 393 193 984 Volume
-3.70% +4.23% +1.48% +3.27% +5.28% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 82,9 M - -
Net income 2021 -81,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,94x
Yield 2021 -
Sales 2022 134 M - -
Net income 2022 -36,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,48x
Yield 2022 -
Capitalization 159 M 159 M -
Capi. / Sales 2021 1,92x
Capi. / Sales 2022 1,18x
Nbr of Employees 206
Free-Float 54,3%
More Financials
Company
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The CompanyÔÇÖs products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The CompanyÔÇÖs lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath... 
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of OptiNose, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about OPTINOSE, INC.
07/30OPTINOSE : Completes Enrollment in Trial of Xhance Nasal Spray in Chronic Sinusi..
MT
07/30OPTINOSE : XHANCE Reaches Important Milestone on Path to be the First FDA-Approv..
PU
07/30OPTINOSE : Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic ..
AQ
07/30OPTINOSE, INC. : Other Events (form 8-K)
AQ
07/30Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic..
CI
07/28OPTINOSE : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4..
PU
07/28OPTINOSE : Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4..
AQ
07/28OptiNose Reiterates Revenue Guidance for the Full Year of 2021
CI
07/28OPTINOSE, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
07/28OptiNose, Inc. Announces Preliminary Revenue Results for the Second Quarter E..
CI
06/25OPTINOSE, INC.(NASDAQGS : OPTN) dropped from Russell 2000 Dynamic Index
CI
06/25OPTINOSE, INC.(NASDAQGS : OPTN) dropped from Russell 2000 Index
CI
06/25OPTINOSE, INC.(NASDAQGS : OPTN) dropped from Russell 3000E Growth Index
CI
06/25OPTINOSE, INC.(NASDAQGS : OPTN) dropped from Russell 3000 Index
CI
06/25OPTINOSE, INC.(NASDAQGS : OPTN) dropped from Russell 3000E Index
CI
More news
News in other languages on OPTINOSE, INC.

- No features available -

More news
Analyst Recommendations on OPTINOSE, INC.
More recommendations
Chart OPTINOSE, INC.
Duration : Period :
OptiNose, Inc. Technical Analysis Chart | OPTN | US68404V1008 | MarketScreener
Technical analysis trends OPTINOSE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,99 $
Average target price 13,67 $
Spread / Average Target 357%
EPS Revisions
Managers and Directors
Peter Kaighn Miller Chief Executive Officer & Director
Ramy A. Mahmoud President & Chief Operating Officer
Keith Alan Goldan Chief Financial Officer
Joseph C. Scodari Independent Chairman
John C. Messina SVP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
OPTINOSE, INC.-27.78%159
JOHNSON & JOHNSON9.46%453 498
ROCHE HOLDING AG13.88%339 298
PFIZER, INC.19.42%246 075
NOVARTIS AG0.14%225 528
ELI LILLY AND COMPANY46.06%224 166